S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

EPRX Eupraxia Pharmaceuticals Inc

3.005

0.00 (0.00%)

Pre Market

Last Updated: 20:05:18

Delayed by 15 minutes

Form D - Notice of Exempt Offering of Securities

Eupraxia Pharmaceuticals (NASDAQ:EPRX)
Historical Stock Chart
From Dec 2024 to Jan 2025

Click Here for more Eupraxia Pharmaceuticals Charts.

Eupraxia Pharmaceuticals (NASDAQ:EPRX)
Historical Stock Chart
From Jan 2024 to Jan 2025

Click Here for more Eupraxia Pharmaceuticals Charts.

Eupraxia Pharmaceuticals Inc News

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 21 November 2024 (2 months ago) • Edgar (US Regulatory)

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months
Wednesday 20 November 2024 (2 months ago) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Friday 15 November 2024 (2 months ago) • Edgar (US Regulatory)

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting
Friday 15 November 2024 (2 months ago) • PR Newswire (US)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 14 November 2024 (2 months ago) • Edgar (US Regulatory)

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024
Thursday 14 November 2024 (2 months ago) • PR Newswire (Canada)

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Wednesday 13 November 2024 (2 months ago) • PR Newswire (US)

Form D - Notice of Exempt Offering of Securities
Saturday 9 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Friday 8 November 2024 (2 months ago) • Edgar (US Regulatory)

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results
Friday 8 November 2024 (2 months ago) • PR Newswire (US)

Form SC 13D - General Statement of Acquisition of Beneficial Ownership
Friday 8 November 2024 (2 months ago) • Edgar (US Regulatory)

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million
Friday 1 November 2024 (2 months ago) • PR Newswire (US)

More Eupraxia Pharmaceuticals Inc News Articles

BEL 20 Total Return Leve...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions